Prognostic Impact of Pre-Treatment CRP/Albumin Ratio in Patients with Advanced-Stage Epithelial Ovarian Cancer
The pre-treatment CRP/Alb ratio is a simple, accessible, and independent prognostic biomarker in advanced-stage EOC. Its integration into routine risk assessment may enhance individualized prognostication and help identify high-risk patients who could benefit from closer monitoring and tailored supportive care. Prospective multicenter validation is warranted.
Authors
- Mahmut Gümüş (ORCID: https://orcid.org/0009-0001-7894-2319)
- Fatih Atalah (ORCID: https://orcid.org/0000-0002-5664-7853)
- Mehmet Beşiroğlu (ORCID: https://orcid.org/0000-0002-1171-8320)
- Aydın Acarbay (ORCID: https://orcid.org/0000-0002-9446-9293)
- Akgün Karakök (ORCID: https://orcid.org/0009-0001-9876-3932)
Institutions
- Istanbul Medeniyet University (TR)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/ott.s567132
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00